All In Biotech

Drug Trial Radar · NCT05337553

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants With Spinal Muscular Atrophy With Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 269 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

269

Actual

Start

Jul 6, 2022

Primary completion

Sep 25, 2024

Study completion Dec 2027

Sponsor

Lead sponsor
Biohaven Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo.

Conditions

  • Spinal Muscular Atrophy
  • Neuromuscular Diseases
  • SMA

Interventions

  • taldefgrobep alfaDrug

    DB Phase: 35 mg/50 mg weekly subcutaneous injection

  • PlaceboDrug

    DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection

  • taldefgrobep alfaDrug

    Extension Phase: 35 mg/50 mg weekly subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of taldefgrobep alfa compared to placebo in change in the 32 item Motor Function Measure (MFM-32) total scoreTime frame: Baseline to Week 48

Locations

53 sites in 9 countries. Site status is shown where the registry gives one.

  • Phoenix Children's

    Phoenix, Arizona

  • UCSD & Rady Children's

    La Jolla, California

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • UCSF Benioff Children's Hospital, Medical Center

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • UF Health, Shands Hospital

    Gainesville, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • Northwestern University - Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Indiana University -Riley Research

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Fairway, Kansas

  • Boston Children's Hospital - Harvard

    Boston, Massachusetts

  • BSHS Office of Research

    Grand Rapids, Michigan

  • Washington University in St. Louis

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Stony Brook University Hospital

    Stony Brook, New York

  • Duke University Medicine

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Penn State College of Medicine

    Hershey, Pennsylvania

  • CHOP Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • UT Pediatric Neurosciences/Dell Children's Medical Center

    Austin, Texas

  • Neurology Rare Disease Center

    Denton, Texas

  • Cook Children's Hospital

    Fort Worth, Texas

  • University of Virginia Children's Hospital

    Charlottesville, Virginia

  • Children's Hospital of The King's Daughters

    Norfolk, Virginia

  • MultiCare Institute of Research and Innovation

    Tacoma, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • University Hospital Antwerp

    Edegem, Belgium

  • University Hospital Ghent

    Ghent, Belgium

  • University Hospital Leuven

    Leuven, Belgium

  • University Hospital Brno - Dept. of Pediatric Neurology

    Brno, Czechia

  • Motol University Hospital

    Prague, Czechia

  • University Hospital Essen (Public-Law Institution) - Dept. of Pediatrics I

    Essen, Germany

  • University Hospital Freiburg, Center For Children and Adolescent Medicine, Dept. of Neuropediatrics and Muscle Disorders

    Freiburg im Breisgau, Germany

  • Dr. Von Haunersches Children'S Hospital - Lmu Munich

    Munich, Germany

  • Irccs Institute of Neurological Sciences of Bologna - Bellaria Hospital

    Bologna, Italy

  • Nemo-Brescia Clinical Center For Neuromuscular Diseases

    Gussago, Italy

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.